WuXi XDC Cayman (HKSE:02268) EBIT : HK$1,311 Mil (TTM As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman EBIT?

WuXi XDC Cayman's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was HK$605 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$1,311 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. WuXi XDC Cayman's annualized ROC % for the quarter that ended in Jun. 2024 was 29.84%. WuXi XDC Cayman's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 64.14%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. WuXi XDC Cayman's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 2.64%.

WuXi XDC Cayman EBIT Historical Data

The historical data trend for WuXi XDC Cayman's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman EBIT Chart

WuXi XDC Cayman Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

38.37

82.46

221.91

394.15

1,305.76

WuXi XDC Cayman Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EBIT	Get a 7-Day Free Trial			86.83	232.03	162.12	604.98	705.76

Competitive Comparison of WuXi XDC Cayman's EBIT

For the Diagnostics & Research subindustry, WuXi XDC Cayman's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WuXi XDC Cayman's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where WuXi XDC Cayman's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

WuXi XDC Cayman EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1,311 Mil.

WuXi XDC Cayman (HKSE:02268) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

WuXi XDC Cayman's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	895.972 * ( 1 - 13.08% )	/	( (2056.768	+	3162.64)	/ 2 )
=	778.7788624	/	2609.704
=	29.84 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7366.952	-	1021.948	-	( 4427.161	-	max(0, 1399.392	-	5687.628	+	4427.161	))
=	2056.768

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7826.447	-	921.116	-	( 3742.691	-	max(0, 1360.214	-	5616.111	+	3742.691	))
=	3162.64

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

WuXi XDC Cayman's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1209.96	/	( ( (1365.451 + max(-195.205, 0))	+	(1905.597 + max(501.727, 0)) )	/	2 )
=	1209.96	/	( ( 1365.451	+	2407.324 )	/	2 )
=	1209.96	/	1886.3875
=	64.14 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(899.314	+	51.193	+	252.316)	-	(1021.948	+	0	+	376.08)
=	-195.205

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1314.652	+	143.967	+	345.956)	-	(921.116	+	0	+	381.732)
=	501.727

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

WuXi XDC Cayman's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	1310.744	/	49556.774
	=	2.64 %

WuXi XDC Cayman EBIT Related Terms

Thank you for viewing the detailed overview of WuXi XDC Cayman's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi XDC Cayman Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (HKSE:02268) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

L74:Germany

Address

No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN

Website

https://www.wuxixdc.com

WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.

Executives

Shang Hai He Quan Yao Ye Gu Fen You Xian Gong Si
He Quan Yao Ye Xiang Gang Tou Zi You Xian Gong Si
Shang Hai Yao Ming Kang De Xin Yao Kai Fa You Xian Gong Si
Wu Xi Yao Ming Kang De Xin Yao Kai Fa Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Morgan Stanley	2201 Interest of corporation controlled by you
Wuxi Biologics (cayman) Inc.	2101 Beneficial owner
Wuxi Apptec Co., Ltd.

WuXi XDC Cayman Headlines

No Headlines